Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome

Colombo Falcone, S. Lucibello, I. Mazzucchelli, S. Bozzini, A. D'Angelo, S. Schirinzi, R. Totaro, R. Falcone, M. Bondesan, G. Pelissero

Research output: Contribution to journalArticle

Abstract

Inflammation plays a key role in atherosclerosis. Galectin-3 is a macrophage- and endothelium-derived mediator actively involved in the regulation of many aspects of inflammatory cell behaviour. The aim of this study is to quantify plasma Galectin-3 in patients with coronary artery disease (CAD) and different clinical manifestation at the moment of observation in order to verify whether Galectin-3 could be a useful biomarker of atherosclerotic state. We enrolled 125 patients affected by CAD, angiographically documented (70 stable, 55 unstable). They underwent accurate examinations and anamnestic data was collected. The most important traditional risk factors, such as age, hypertension, and body mass index, were reported. Plasma Galectin-3 was quantified using an ELISA kit. Unstable patients (n = 55) had a higher plasma Galectin-3 levels in respect to the stable subjects (27.75 ng/mL (19.27-39.09) vs 6.48 ng/ml (4.88-8.83), p

Original languageEnglish
Pages (from-to)905-913
Number of pages9
JournalInternational Journal of Immunopathology and Pharmacology
Volume24
Issue number4
Publication statusPublished - Oct 2011

Keywords

  • CAD
  • Galectin-3
  • Stable and unstable angina

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome'. Together they form a unique fingerprint.

  • Cite this

    Falcone, C., Lucibello, S., Mazzucchelli, I., Bozzini, S., D'Angelo, A., Schirinzi, S., Totaro, R., Falcone, R., Bondesan, M., & Pelissero, G. (2011). Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome. International Journal of Immunopathology and Pharmacology, 24(4), 905-913.